Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

New perspectives in gastric acid suppression: genetic polymorphisms predict the efficacy of proton pump inhibitors.

Digestive diseases (Basel, Switzerland) - 1 Jan 2000

Egan L J, Murray J A

Abstract excerpt

Proton pump inhibitors are highly effective in the management of acid-peptic diseases. These drugs potently inhibit acid secretion from gastric parietal cells by irreversibly inhibiting activity of the H(+), K(+) ATPase (proton pump). Early studies of the pharmacokinetics of proton pump inhibitor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 Enzyme System
Share to Enzyme Inhibitors
Share to Gastric Acid

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Omeprazole

Share to Polymorphism, Genetic

Share to Prognosis

Share to Proton Pump Inhibitors

Share to Stomach Ulcer

Source

Identifiers

PMID: 11060468
DOI: 10.1159/000016966

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-11060468-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

New perspectives in gastric acid suppression: genetic polymorphisms predict the efficacy of proton pump inhibitors.PMID 11060468Read ↗

Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine.Semantic proximity Read ↗

CYP2C19 genotype-guided dosing of proton pump inhibitors: progress in clinical trials and real-world use.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing.Semantic proximity Read ↗

Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.Semantic proximity Read ↗

CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection.Semantic proximity Read ↗

Use of Pharmacogenomics to Guide Proton Pump Inhibitor Therapy in Clinical Practice.Semantic proximity Read ↗

Individualized therapy for gastroesophageal reflux disease: potential impact of pharmacogenetic testing based on CYP2C19.Semantic proximity Read ↗

Genetic polymorphism of CYP2C19 & therapeutic response to proton pump inhibitors.Semantic proximity Read ↗

Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problemSemantic proximity Read ↗

Prevalence of CYP2C19 polymorphisms in medically and surgically managed patients with GERD.Semantic proximity Read ↗

CYP2C19 pharmacogenetics in the clinical use of proton-pump inhibitors for gastro-oesophageal reflux disease: variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms.Semantic proximity Read ↗

New Guidance on Cytochrome P450 2C19 Phenotype-based Use of Proton Pump Inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.